A small British company is chasing a costly healthcare challenge: how to keep patients on weight-loss drugs without straining the budgets of insurers footing the bill.
Less is More, a UK venture with a team that hasn't yet reached double digits, has built software designed to identify the lowest GLP-1 dose each patient needs once they've shed the pounds. The pitch is straightforward, if unproven: personalized dose reduction could shave thousands off annual treatment costs while keeping the weight off. Insurers and employers managing the rising costs of Wegovy and Ozempic represent the target market.
The company recently posted a job listing for a chief medical officer that doubled as a window into its strategy. Patients would log appetite levels, track what the industry calls "food noise"—the mental chatter around food—and share weight and activity metrics. The platform would then recommend dose adjustments for a clinician to approve or reject. "The software suggests; the doctor decides," the posting said, a phrasing that hints at awareness of regulatory boundaries.
Standard GLP-1 protocols call for a fixed maintenance dose after initial titration. Less is More wants to challenge that convention by continually tweaking doses downward to locate each patient's personal threshold. Whether that works in practice is another matter, which is why the company plans to run an internal pilot tracking around 150 patients for a year before approaching potential partners with data in hand.
The White-Label Gambit
Rather than court consumers directly, Less is More intends to sell its service to insurers, employers, pharmacies, and wellness platforms as a white-label offering. It's a path that avoids the bruising customer acquisition costs of the direct-to-consumer telehealth model but demands a different kind of credibility. Partners will want evidence, the job posting acknowledged, so the company plans to generate its own: a 12-month report documenting weight retention, final dose levels, side effects, and cost savings. The dosing engine itself has been built and tested in simulation, according to the company.
The approach reflects a pragmatic read of the market. Payers are under pressure to manage GLP-1 spending without cutting off patients who've reached their goals—a scenario that could push them back toward weight regain and the metabolic complications that follow. Finding a maintenance dose lower than the standard protocol, if it holds up clinically, would offer a financial release valve. Whether 150 patients over 12 months will constitute persuasive evidence remains an open question.
A Crowded Field
Less is More enters a space that has gotten noisy quickly. White-label GLP-1 programs have proliferated: LegUpRx, Dosevana, MyOrbitHealth, Insert MD, EmbedCare, Impetus One, Karpa Health, Nimbus OS, and MDLaunchr all vie for partnerships, each with its own angle on managing titration, adherence, or cost. Omada Health, a more established player, rolled out a GLP-1 offering for employers earlier this year.
Consumer-facing tools have also multiplied. DoseCurve, Dosavy, and The Dose Club help patients visualize their titration schedules, while Nimbus OS mentions "titration-adjusted dosing" in its marketing materials. Several startups have staked claims on the maintenance phase specifically: OffRamp bills itself as the "maintenance OS for life after a GLP-1," Healthcount tracks food and doses during maintenance, and Conduit offers what it describes as a "physician-managed" weight maintenance protocol.
The question is whether Less is More's focus on dose optimization represents a meaningful differentiation or simply another variation on a theme. The company appears to be betting that payers will pay for proof that lower doses work, which may explain the decision to generate its own pilot data rather than partner immediately.
Regulatory Terrain and Evidence Gaps
The chief medical officer role includes navigating UK regulatory requirements, among them potential medical device classification and compliance with the General Medical Council, Care Quality Commission, General Pharmaceutical Council, and Medicines and Healthcare products Regulatory Agency. The company's job posting suggests it expects regulatory conversations to be part of the process, though it offered no detail on how it plans to classify the software or what path it will follow.
Academic interest in alternative GLP-1 dosing exists, though research on intentionally reduced maintenance protocols remains limited. A 2025 study in the journal Obesity explored variations on standard regimens. A health news article quoted nference's Venky Soundararajan on outcomes at lower doses—roughly 2 to 7 percent weight loss with improved tolerability—but commentators have noted the absence of standardized definitions for terms like "microdosing" and limited randomized trial data on intentionally reduced maintenance protocols. Less is More will need more than simulation data and a 150-patient pilot if it wants to move the needle with skeptical payers.
Funding and Founders
The company is raising a seed round, according to its CMO posting, which offered equity alongside salary "once our seed round closes." The listing referenced a "clinical founder" without naming them. Mark Bjornsgaard appears on the company's LinkedIn employee roster, though his specific role was not disclosed. The LinkedIn page itself, viewed recently, listed fewer than 10 employees.
Startups addressing GLP-1 adherence, cost, and maintenance have attracted investor attention as the drugs themselves become a fixture of employer health plans. Whether Less is More can carve out a defensible position in a field filling up with competitors will depend on the strength of its pilot data, the regulatory path it clears, and whether payers believe dose reduction can deliver savings without backsliding. For now, it remains a small team with a big hypothesis and a year to prove it.
